Houston TX 胃癌临床试验
42项针对 胃癌的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
招募中2 期
- Research Site, Houston
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
招募中2/3 期
- University of Texas MD Anderson Cancer Center, Houston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
招募中3 期
- MD Anderson Cancer Center, Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
招募中2 期
- Research Site, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
招募中1 期
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- MD Anderson, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
招募中3 期
- Research Site, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- MD Anderson Cancer Center - University of Texas, Houston
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
招募中1 期
- UT MD Anderson Cancer Center, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Houston
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
招募中1/2 期
- Oncology Consultants, Houston
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
招募中1 期
- Investigative Site #129, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
招募中2 期
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
招募中2 期
- M D Anderson Cancer Center, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
招募中3 期
- The University of Texas MD Anderson cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
招募中1 期
- Baylor St. Luke's Medical Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
招募中欢迎健康志愿者
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
其他城市的 胃癌试验
- Boston, MA32 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Baldwin Park, CA22 项研究
- Los Angeles, CA22 项研究
- Arlington, VA20 项研究
- Dallas, TX19 项研究
- San Antonio, TX19 项研究
- Grand Rapids, MI18 项研究
- St. Louis, MO18 项研究
- Chicago, IL16 项研究
- Washington, DC16 项研究
Houston的其他研究
- 非小细胞肺癌145 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）121 项研究
- 转移性癌症104 项研究
- 结直肠癌102 项研究
- 卵巢癌89 项研究
- 急性髓系白血病85 项研究
- 肺癌78 项研究
- 前列腺癌76 项研究
- 子宫内膜癌68 项研究
- 胰腺癌61 项研究
- 黑色素瘤59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。